-

09:55:46 AM

CYTK Stock News

CYTK - Cytokinetics Inc

08/04/22 4:00 PM

Nasdaq : CYTK

earnings

Cytokinetics Reports Second Quarter 2022 Financial Results

RHEA-AI

neutral

08/04/22 7:30 AM

Nasdaq : CYTK

clinical trial

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials

Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced a new release of the Pooled Resource Open-Access ALS

RHEA-AI

positive

08/01/22 4:00 PM

Nasdaq : CYTK

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 29, 2022 it granted stock options to purchase an aggregate of 88,200 shares of common stock to 11 new employees, whose employment commenced in July 2022, as a

RHEA-AI

very positive

07/21/22 4:00 PM

Nasdaq : CYTK

earnings

Cytokinetics to Announce Second Quarter Results on August 4, 2022

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 4, 2022 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a

RHEA-AI

neutral

07/05/22 4:00 PM

Nasdaq : CYTK

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2022 it granted stock options to purchase an aggregate of 180,450 shares of common stock to 19 new employees, whose employment commenced in June 2022, as a

RHEA-AI

very positive

07/01/22 3:35 AM

Nasdaq : CYTK

Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering

Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $450.0 million aggregate principal amount of 3.50% convertible senior notes due 2027 (the “notes”) in a private offering to

RHEA-AI

neutral

06/29/22 4:35 PM

Nasdaq : CYTK

Cytokinetics Announces Proposed Convertible Senior Notes Offering

Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) in

RHEA-AI

neutral

06/24/22 7:30 AM

Nasdaq : CYTK

Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the previously announced meeting of the

RHEA-AI

neutral

06/17/22 7:30 AM

Nasdaq : CYTK

Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the company recently

RHEA-AI

neutral

06/16/22 7:30 AM

Nasdaq : CYTK

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of COURAGE-ALS OLE ( C linical O utcomes U sing R eldesemtiv on

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next